Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...

The company’s pipeline products include ABX-002, a CNS-directed thyroid hormone receptor beta (TRß) agonist against treats Adjunctive major depressive disorder (MDD), bipolar depression and other ...

A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...